Literature DB >> 9227542

Ca2+ release mechanism of primate drug-induced coronary vasospasm.

K Miyagawa1, J Vidgoff, K Hermsmeyer.   

Abstract

Cellular mechanisms of protection against drug-stimulated coronary vasospasm were studied by multiweek estrogen plus progesterone (P) vs. medroxy-progesterone acetate (MPA) treatments by measuring intracellular Ca2+ and protein kinase C (PKC) signals. Ovariectomized monkeys (OVX) were treated by slow-release implants with either P or MPA for 4 wk added to estradiol-17 beta (E2) begun 2 wk earlier. A third group received E2 for 2 wk and withdrawal of E2 (W; no steroid treatment) during the last 4 wk. OVX coronary artery vascular muscle cells (VMC) in primary culture conditions were labeled by the fluorescent indicators, fluo 3 and hypericin, respectively, to study intracellular Ca2+ and PKC mechanisms of coronary artery hyperre-activity, using digital analysis of single VMC by photon-counting camera. Stimulation by 10 microM serotonin and 100 nM U-46619 (thromboxane A2 mimetic) caused Ca2+ increases (2-5 min) and no PKC activation in VMC from five P-treated monkeys but prolonged (> or = 30 min) increases in both Ca2+ and PKC signals in VMC from six MPA-treated monkeys or seven W-treated monkeys; these P vs. MPA (or W) differences were maintained > or = 14 days. We hypothesize that hyperreactivity in VMC from MPA- or W-treated monkeys results from accelerated prolonged Ca2+ release, with concomitant PKC activation, and that MPA (but not P) negates the coronary vasospasm protective effect of E2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227542     DOI: 10.1152/ajpheart.1997.272.6.H2645

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone.

Authors:  R Kent Hermsmeyer; Rajesh G Mishra; Dusan Pavcnik; Barry Uchida; Michael K Axthelm; Frank Z Stanczyk; Kenneth A Burry; D Roger Illingworth; Carlos Juan; Frank J Nordt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-03-18       Impact factor: 8.311

Review 2.  Progesterone and neuroprotection.

Authors:  Meharvan Singh; Chang Su
Journal:  Horm Behav       Date:  2012-06-23       Impact factor: 3.587

3.  GABAB receptors are expressed in human aortic smooth muscle cells and regulate the intracellular Ca(2+) concentration.

Authors:  Xu-Ping Wang; Zhen-Ying Cheng; Katrina L Schmid
Journal:  Heart Vessels       Date:  2014-03-30       Impact factor: 2.037

Review 4.  Progesterone-induced neuroprotection.

Authors:  Meharvan Singh
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

5.  Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys.

Authors:  Rajesh G Mishra; R Kent Hermsmeyer; Koichi Miyagawa; Philip Sarrel; Barry Uchida; Frank Z Stanczyk; Kenneth A Burry; D Roger Illingworth; Frank J Nordt
Journal:  J Clin Endocrinol Metab       Date:  2005-03-15       Impact factor: 5.958

Review 6.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

Review 7.  Ovarian steroids and serotonin neural function.

Authors:  C L Bethea; M Pecins-Thompson; W E Schutzer; C Gundlah; Z N Lu
Journal:  Mol Neurobiol       Date:  1998-10       Impact factor: 5.590

Review 8.  Progesterone, brain-derived neurotrophic factor and neuroprotection.

Authors:  M Singh; C Su
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

Review 9.  Sex differences in cognitive impairment and Alzheimer's disease.

Authors:  Rena Li; Meharvan Singh
Journal:  Front Neuroendocrinol       Date:  2014-01-13       Impact factor: 8.606

Review 10.  Progesterone-induced neuroprotection: factors that may predict therapeutic efficacy.

Authors:  Meharvan Singh; Chang Su
Journal:  Brain Res       Date:  2013-01-20       Impact factor: 3.252

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.